Project description
Innovative diagnostic test for allergies
The World Health Organization predicts that allergies will affect half the European population. This growing problem imposes a significant burden on society, the healthcare system and companies, as employees may need to take time off due to disabling symptoms. The EU-funded Nexdiag project aims to address this challenge by developing a highly multiplexed diagnostic test capable of testing for IgE antibodies against up to 500 allergens (and potentially up to 1 000), using just one drop of blood. The test employs fluorescent µpearls and Quantum Plates, reducing the time and cost associated with allergy diagnostics (between 10 and 20 times less expensive). Moreover, this technology may be employed in serology tests for detecting antibodies against infectious agents and cancer markers.
Objective
The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system and companies that have to take staff off work due to disabling symptoms.
Thanks to fluorescent µpearls and the discovery of Quantum Plates, Nexdot is developing a highly multiplexed diagnostic test that will allow to assay IgE on 500 allergens (and up to 1000) at once using only one drop of blood. This innovation will revolutionize the way allergies are treated by reducing drastically the time to diagnostic and its associated cost (x10-20 reduction).
Our technology could also be extended to serology tests, for detection of patient’s antibodies against infectious agents or cancer markers. It can be extended for global health for the easy and cost-effective detection of antigens as infectious or toxic agents in human, animals or environment for global health, or food for industry.
Fields of science
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
93230 Romainville
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.